132 related articles for article (PubMed ID: 37608127)
21. A mathematical model of the kinetics and tissue distribution of 2-fluoro-beta-alanine, the major catabolite of 5-fluorouracil.
Zhang R; Liu T; Soong SJ; Diasio RB
Biochem Pharmacol; 1993 May; 45(10):2063-9. PubMed ID: 8512588
[TBL] [Abstract][Full Text] [Related]
22. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
Sculpher M; Palmer MK; Heyes A
Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
[TBL] [Abstract][Full Text] [Related]
23. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
24. alpha-Fluoro beta alanine in urine of workers occupationally exposed to 5 fluorouracil in a 5 fluorouracil producing factory.
R P Bos B F J Weissenberger R B M Anzion
Biomarkers; 1998; 3(1):81-7. PubMed ID: 23899259
[TBL] [Abstract][Full Text] [Related]
25. Biomonitoring of occupational exposure to 5-FU by assaying α-fluoro-β-alanine in urine with a highly sensitive UHPLC-MS/MS method.
Dhersin A; Atgé B; Martinez B; Titier K; Rousset M; Sidatt Cheikh El Moustaph M; Verdun-Esquer C; Molimard M; Villa A; Canal-Raffin M
Analyst; 2018 Aug; 143(17):4110-4117. PubMed ID: 30058665
[TBL] [Abstract][Full Text] [Related]
26. Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
Carlomagno C; Lauria R; De Laurentiis M; Arpino G; Massarelli E; Ferrara C; Milano A; Vernaglia Lombardi A; Costanzo R; Catalano G; Bianco AR; De Placido S
Oncology; 2002; 63(3):219-25. PubMed ID: 12381900
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil.
Zhang RW; Soong SJ; Liu TP; Barnes S; Diasio SB
Drug Metab Dispos; 1992; 20(1):113-9. PubMed ID: 1346985
[TBL] [Abstract][Full Text] [Related]
28. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
[TBL] [Abstract][Full Text] [Related]
29. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
van Kuilenburg AB; Häusler P; Schalhorn A; Tanck MW; Proost JH; Terborg C; Behnke D; Schwabe W; Jabschinsky K; Maring JG
Clin Pharmacokinet; 2012 Mar; 51(3):163-74. PubMed ID: 22339448
[TBL] [Abstract][Full Text] [Related]
31. Serum alanine aminotransferase levels, hematocrit rate and body weight correlations before and after hemodialysis session.
Lopes EP; Sette LH; Sette JB; Luna CF; Andrade AM; Moraes M; Sette PC; Menezes R; Cavalcanti RL; Conceição SC
Clinics (Sao Paulo); 2009; 64(10):941-5. PubMed ID: 19841699
[TBL] [Abstract][Full Text] [Related]
32. Evidence for the importance of 5'-deoxy-5-fluorouridine catabolism in humans from 19F nuclear magnetic resonance spectrometry.
Malet-Martino MC; Armand JP; Lopez A; Bernadou J; Béteille JP; Bon M; Martino R
Cancer Res; 1986 Apr; 46(4 Pt 2):2105-12. PubMed ID: 2936452
[TBL] [Abstract][Full Text] [Related]
33. Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis.
Liberato IR; Lopes EP; Cavalcante MA; Pinto TC; Moura IF; Loureiro Júnior L
Clinics (Sao Paulo); 2012; 67(2):131-4. PubMed ID: 22358237
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy for colorectal cancer.
Goyle S; Maraveyas A
Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
[TBL] [Abstract][Full Text] [Related]
35. Biological monitoring of occupational exposure to 5-fluorouracil: urinary α-fluoro-β-alanine assay by high performance liquid chromatography tandem mass spectrometry in health care personnel.
Ndaw S; Denis F; Marsan P; d'Almeida A; Robert A
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Oct; 878(27):2630-4. PubMed ID: 20207593
[TBL] [Abstract][Full Text] [Related]
36. The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells.
Reis-Mendes A; Carvalho F; Remião F; Sousa E; Bastos ML; Costa VM
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30862114
[TBL] [Abstract][Full Text] [Related]
37. [The effect of hemodialysis on some parameters of the antioxidant system in the blood of patients with chronic renal failure].
Olszewska M
Ann Acad Med Stetin; 2004; 50(1):41-52. PubMed ID: 16871743
[TBL] [Abstract][Full Text] [Related]
38. Increasing doses of 5-fluorouracil and high-dose folinic acid in the treatment of metastatic colorectal cancer.
Meregalli M; Martignoni G; Frontini L; Zonato S; Pavia G; Beretta G
Tumori; 1998; 84(6):662-5. PubMed ID: 10080672
[TBL] [Abstract][Full Text] [Related]
39. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
Hull WE; Port RE; Herrmann R; Britsch B; Kunz W
Cancer Res; 1988 Mar; 48(6):1680-8. PubMed ID: 3125967
[TBL] [Abstract][Full Text] [Related]
40. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.
Murray PT; Reddy BV; Grossman EJ; Hammes MS; Trevino S; Ferrell J; Tang I; Hursting MJ; Shamp TR; Swan SK
Kidney Int; 2004 Dec; 66(6):2446-53. PubMed ID: 15569338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
